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Abstract
Ventilator-associated pneumonia (VAP) is a common cause of
morbidity, antibiotic use, increased length of stay and, possibly,
increased mortality in ICU patients. Colonization of the oropharyn-
geal cavity with potentially pathogenic micro-organisms is instru-
mental in the pathogenesis of VAP, and selective oropharyngeal
decontamination (SOD) with antibiotics (AB-SOD) or antiseptics,
such as chlorhexidine gluconate (CHX-SOD), has been associated
with reduced incidences of VAP. In a recent issue of Critical Care
Scannapieco and colleagues investigated differences in oro-
pharyngeal colonization between mechanically ventilated patients
receiving oropharyngeal decontamination with 0.12% CHX-SOD
either once or twice daily compared to placebo. CHX-SOD was
associated with a reduction in Staphylococcus aureus coloniza-
tion, but the study was underpowered to demonstrate a reduction
in VAP incidence. We urgently need well-designed and adequately
powered studies to evaluate the potential benefits of CHX-SOD on
patient outcome in ICUs.
In this commentary we discuss the study of Scannapieco and
colleagues [1] published in a recent issue of Critical Care.
Ventilator-associated pneumonia (VAP) frequently occurs in
ICUs, with reported incidences ranging from 9% to 27% [2]. It
is a leading cause of morbidity and, possibly, of mortality. As a
result, many interventions have been designed and evaluated
for the prevention of VAP. One of the most successful
interventions in this regard is oral decontamination.
Colonization of the upper respiratory tract generally precedes
the occurrence of VAP, most probably because of a reduced
capacity to clear pathogens and/or an increased adherence
of micro-organisms to the respiratory tract [3]. Prevention of
oropharyngeal colonization has been achieved with topically
applied non-absorbable antibiotics (referred to as selective
oropharyngeal decontamination with antibiotics (AB-SOD)) or
with topically applied chlorhexidine gluconate (CHX-SOD).
AB-SOD was associated with reduced incidences of VAP in
various studies [4-6], and recently also with a better 28-day
survival in a large Dutch multi-center study [7]. In that study,
AB-SOD was equally effective in improving patient outcome
as selective decontamination of the digestive tract (SDD),
which combines AB-SOD with intestinal decontamination
and 4 days of intravenous cefotaxim. The occurrence of
resistance as a result of AB-SOD or SDD, however, remains
of concern, especially in countries with endemic levels of
antimicrobial-resistant bacteria (AMRB). Therefore, simply
replacing antibiotics with antiseptics for oral decontamination
might offer an effective and safe measure for ICU patients,
even in settings with high levels of AMRB.
Indeed, CHX-SOD appeared effective in reducing VAP
incidence in several studies [8-13]. However, the regimens
used were not always carefully described and concentrations
and dosing frequencies varied from 0.12% CHX twice daily
to 2% CHX four times a day. In addition, patient populations
varied widely: from mixed ICU populations [9,12] to surgical
ICU patients [10] and patients undergoing cardiac surgery
[8,11,13]. Furthermore, nasal application of CHX was used in
one study [13] and CHX was combined with Colistine in
another [12], and in one study effects were compared to
historic controls [10]. Moreover, all individual studies pub-
lished so far have been underpowered to demonstrate effects
of CHX-SOD on patient survival. In a recently published
systematic review and meta-analysis, CHX-SOD was asso-
ciated with a significant reduction in VAP incidence of 44%,
although the studies were very heterogeneous, which
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precludes firm conclusions about its protective effects. No
reductions in overall mortality, duration of mechanical ventila-
tion or length of stay could be demonstrated [2].
In their article, Scannapieco and colleagues [1] aimed to
determine the optimal frequency of CHX-SOD to prevent
VAP in trauma ICU patients. The study contains a control
group (49 patients) and two intervention groups receiving
CHX 0.12% either once (47 patients) or twice daily (50
patients). They conclude that the number of Staphylococcus
aureus in dental plaque was reduced in both intervention
groups, but no significant reductions were observed in the
total number of respiratory pathogens or incidence of VAP.
Estimated reductions in colonization were 25% and 30% in
the ‘twice-daily’ and ‘once-daily’ groups, respectively. The
odds ratio for developing VAP was 0.54 (95% confidence
interval 0.23 to 1.25) for patients receiving CHX-SOD, which
is remarkably similar to the pooled estimate from the most
recent meta-analysis. Although this may suggest a beneficial
effect of CHX-SOD, it cannot be demonstrated by a study of
this sample size.
In summary, the evidence that both AB-SOD and CHX-SOD
reduce VAP incidence in ICU patients is accumulating. The
optimal frequency and concentration for CHX-SOD remains
to be demonstrated. From Scannapieco and colleagues’
study we can conclude that twice daily is not necessarily
better than once daily, but maybe a four times daily regimen
with 2% instead of 0.12% CHX does make a difference.
What we need now are well-designed and adequately
powered studies to evaluate the effects of these measures on
length of ICU stay and survival. If these effects were demon-
strated, CHX-SOD would offer a very cheap and (ecolo-
gically) safe infection prevention measure in patient popula-
tions increasingly suffering from infections caused by AMRB.
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